Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

  • STATUS
    Recruiting
  • End date
    Sep 19, 2024
  • participants needed
    21
  • sponsor
    Mark Stein
Updated on 20 October 2021

Summary

Primary

To evaluate the safety and tolerability of ADXS-504 and to determine the MTD or RP2D.

Description

ADXS-504 is a novel Listeria monocytogenes (Lm) - based immunotherapy, bioengineered to elicit T cell responses against 24 tumor antigens that include 1) 14 peptide antigens derived from frequently occurring and commonly shared hotspot mutations in patients with prostate cancer and 2) 10 peptide antigens derived from sequence-optimized TAAs that are differentially expressed or overexpressed in prostate cancer. ADXS-504 is designed to express multiple tumor antigen targets to which patients may generate a broad set of effector T cells for tumor control.

This is a Phase 1 open-label study of ADXS-504 monotherapy in subjects with biochemically recurrent prostate cancer previously treated with radical prostatectomy (RP) or radiation therapy (external beam or brachytherapy) who are not currently receiving androgen ablation therapy. The purpose of this study is to evaluate safety, tolerability, and preliminary clinical and immune responses following treatment with ADXS-504 monotherapy.

Details
Condition Recurrent Prostate Cancer
Treatment ADXS-504
Clinical Study IdentifierNCT05077098
SponsorMark Stein
Last Modified on20 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately
Age 18years at the time of consent
ECOG Performance Status of 0-1 within 28 days prior to registration
Histologically documented prostatic adenocarcinoma confirmed by a pathology report from prostate biopsy or a radical prostatectomy specimen
Previously undergone primary therapy for prostate cancer. Salvage external beam radiation or cryotherapy following primary therapy 6 months prior to randomization is allowed
Patients with low-risk biochemical recurrence, defined as a prostate specific antigen doubling time (PSADT) 10 months in patients who were previously treated with radical prostatectomy or radiation therapy
A rising PSA defined as the following
If the subject's primary therapy was radical prostatectomy (with or without adjuvant or salvage XRT), rising PSA is defined as 2 consecutive rising values above 0.2 ng/mL, each taken 3 weeks apart, and the last value 0.8 ng/mL
If the subject received other primary therapies (e.g. XRT, cryosurgery, brachytherapy), rising PSA is defined per the Phoenix definition, i.e., 2 consecutive rising values above the PSA nadir plus 2.0 ng/mL
Testosterone 150 ng/dL 28 days of prior to registration
Adequate bone marrow, hepatic, and renal function
ANC >1,500 cells/mm3
Hemoglobin >9.0 g/dL
Platelet count >100,000 cells/mm3
Serum creatinine <2 upper limit of normal (ULN)
Serum total bilirubin <1.5 ULN
ALT <2.5 ULN
AST <2.5 ULN
Subject has baseline blood oxygen saturation on room air of 95%
Subject is willing and able to provide an archived biopsy specimen which may be used for correlative studies and to determine HLA type
Subject with a female partner of child-bearing potential is eligible if he agrees to follow the contraceptive guidance, provided in the study, during the treatment period and for at least 120 days after the final dose of study treatment

Exclusion Criteria

Patients with evaluable metastatic disease on bone or computed tomography (CT) or PET scans performed 8 weeks of registration (patients with PET scan findings consistent with metastasis but who have normal conventional imaging by CT/MRI/Bone scan using standard radiographic criteria ARE eligible)
Patients with known brain metastases
Patients with active autoimmune disease requiring systemic treatment within the past 3 months, a documented history of clinically severe autoimmune disease, or a disorder that requires systemic corticosteroids or immunosuppressive agents
Patients with active infection requiring systemic therapy or is dependent on or currently receiving antibiotics that cannot be discontinued before dosing. (Note: Subjects who discontinue an antibiotic prior to dosing must wait at least 5 half-lives after the last dose of antibiotic before receiving any study treatment
Subject has a contraindication (e.g., sensitivity/allergy) to trimethoprim/ sulfamethoxazole and ampicillin
Subject has uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic pressure >90 mmHg, despite optimal medical management
Subject has a history of listeriosis
Subject has an implanted medical device that poses a high risk for bacterial colonization and/or that cannot be easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopedic screws, metal plates, bone grafts, or other exogenous implants). NOTE: More common devices and prosthetics that include arterial and venous stents, dental and breast implants and venous access devices (e.g., Port-a-Cath or Mediport) are permitted. Sponsor must be contacted prior to consenting any subject who has any other device or implant
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note